TetraLogic Pharmaceuticals (United States)

Recent papers from TetraLogic Pharmaceuticals (United States)

1. Meta-regression model choice and the interpretation of trial-level surrogacyBMC Medical Research Methodology · 2026
2. Phase 2a Randomized Controlled Trial of TPN ‐101, A Nucleoside Reverse Transcriptase Inhibitor, in Progressive Supranuclear PalsyMovement Disorders · 2026
3. Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC)The Journal of Liquid Biopsy · 2026
4. Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping reviewAlzheimer s & Dementia · 2026
5. Estimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them?Alzheimer s & Dementia · 2026
6. Efficacy assessment in trials of complex and rare diseases: a comparison between the meta-analytic global statistical test and co-primary analysisFrontiers in Medical Technology · 2026
7. Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials (P1-12.015)Neurology · 2026
8. Long-term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved (P2-12.003)Neurology · 2026
9. Feasibility of an Entirely Remote, Decentralized, Phase 3 Trial of a Light Therapy Device for Parkinson’s Disease (P2-9.021)Neurology · 2026
10. Estimating the 10-Year Time-savings Benefits of Lecanemab Treatment (S1.006)Neurology · 2026
11. RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known WellStroke Vascular and Interventional Neurology · 2026
12. A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeaeNature Microbiology · 2026
13. Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio‐Hermes Study participantsAlzheimer s & Dementia · 2026
14. Time and money address clinical meaningfulness better than points on clinical outcome assessments particularly with disease modification in early diseaseJournal of the Neurological Sciences · 2025
15. Why your Alzheimer’s disease study is going to failJournal of the Neurological Sciences · 2025
16. Designing primary and secondary Alzheimer’s disease prevention studies for success with optimal measurement of risk, early pathology and clinical declineJournal of the Neurological Sciences · 2025
17. Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)Neurology and Therapy · 2026
18. Handling Missing Data in Participants with Baseline but No Post‐Baseline DataPharmaceutical Statistics · 2026
19. Suppression of interferon signaling via small-molecule modulation of TFAMeLife · 2026
20. Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s diseaseThe Journal of Prevention of Alzheimer s Disease · 2026